A Study in Moderate to Severe Rheumatoid Arthritis Participants

NCT01721057 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

684

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Placebo
DRUG: Baricitinib
DRUG: cDMARD

Sponsor

Eli Lilly and Company